Evidence-Based Complementary and Alternative Medicine

Research Article

Acupuncture for Frequent Migraine: A Randomized, Patient/Assessor Blinded, Controlled Trial with One-Year Follow-Up

Table 7

Secondary outcome measurements.


	After treatment ()				At three months follow-up period I ()				One year follow-up period II ()
	RA mean (SD)	SA mean (SD)	95% CI for difference	value	RA mean (SD)	SA mean (SD)	95% CI for difference	value	RA mean (SD)	SA mean (SD)	95% CI for difference	value
			95% CI for difference	value			95% CI for difference	value			95% CI for difference	value

McGill
PRI-S	13.1 (8.8)	15.8 (11.6)	(−8.6, 3.1)	0.350	11.1 (4.2)	14.1 (9.0)	(−7.1, 1.1)	0.150	21.6 (8.1)	19.7 (10.8)	(−6.0, 9.8)	0.620
PRI-A	3.96 (3.0)	4.8 (2.8)	(−2.5, 0.8)	0.320	3.3 (2.1)	4.4 (3.1)	(−2.6, 0.4)	0.163	6.5 (2.5)	6.2 (3.4)	(−2.2, 2.7)	0.820
PRI-E	2.08 (1.3)	2.8 (1.5)	(−1.53, .02)	0.056	1.6 (0.9)	2.6 (1.3)	(−1.6, −.38)	0.002^*	3.6 (1.2)	3.8 (1.2)	(−1.2, 0.8)	0.700
PRI-M	5.6 (3.4)	6.1 (3.5)	(−2.47, 1.45)	0.60	5.5 (0.9)	5.9 (2.9)	(−1.9, 1.2)	0.651	7.3 (2.5)	8.1 (2.9)	(−3.2, 1.4)	0.440
Total	20.8 (15.7)	33.4 (17.4)	(−22.1, −3.2)	0.010^*	15.0 (4.5)	22.4 (14.5)	(−13.5, −1.4)	0.017	38.9 (11.8)	37.8 (16.0)	(−10.4, 12.7)	0.843
MSQOL
FR	72.2 (16.4)	58.0 (21.0)	(3.6, 24.9)	0.010^*	74.2 (15.3)	56.3 (23.2)	(6.5, 29.2)	0.003^*	46.4 (15.2)	50.1 (19.0, −0.5)	(−18.0, 10.6)	0.600
FP	77.1 (16.8)	68.3 (22.7)	(−2.7, 20.3)	0.13	80.8 (15.3)	63.1 (23.2)	(5.1, 30.2)	0.007^*	62.0 (15.4)	64.3 (17.8)	(−16.3, 11.71)	0.740
EF	78.3 (19.3)	60.5 (25.6)	(4.98, 30.6)	0.007^*	79.3 (18.7)	58.8 (27.3)	(7.1, 34.0)	0.002^*	49.5 (17.0)	56.6 (21.0)	(−23.1, 8.8)	0.370
Medication
MQS	20.8 (46.4)	68.9 (81.2)	(−85.4, −10.9)^*	0.012	11.0 (24.3)	54.3 (62.4)	(−69.8, −16.8)	0.002^*	78.2 (79.1)	75.1 (50.8)	(−59.5, 67.7)	0.920
Pill count	4.54 (12.21)	10.54 (19.31)	(−15.12, 3.11)	0.192	3.46 (9.84)	10.10 (17.63)	(−14.93, 1.64)	0.113	10.56 (14.81)	7 (9.90)	(−7.91, 15.03)	0.530
Number of participants who took pain killers	9	18	8.2^∧	0.004^#
Number of participants who took specific antimigraine drugs	1	4	2.28^∧	0.13
Number of participants who took prophylactic drugs	7	9	.64^∧	0.42

^*Indicates statistical significance assessed at 0.05/4 = 0.0125 (Bonferroni correction) for both intention to treat () and per protocol analysis (); ^#indicates statistical significance assessed at 0.05; ^∧indicates value; : indicates that the data are based on the per protocol analysis; PRI-S: sensory components; PRI-A: affective components; PRI-E: evaluative components; PRI-M: miscellaneous components; FR: function-restrictive in Migraine Specific Quality of Life questionnaire; FP: function-preventive in Migraine Specific Quality of Life questionnaire; EF: emotional function in Migraine Specific Quality of Life questionnaire; PPT: pressure pain threshold; MQS: Medication Quantification Scale.